Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that its Director Geodata Drew Heasman, who leads its Digital Discovery team, has been awarded the top prize at the 2023/2024 Future Explorer's Compe...
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients...
SEATTLE , June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al....
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has commenced Phase I of its 2024 Angilak Diamond Drilling Exploration Program at its Angilak Project in Nunavut. The program involves around 10,000 meters of ...
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024 Management to Highlight Robust Pip...
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has signed an option agreement with Riverboat Energy Corporation, granting Riverboat the exclusive option to acquire a 70% interest in ATHA's Vista property in...
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a...
Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Dru...
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...
